SureTrader
Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs > Viking Therapeutics, Inc. (VKTX)

Just because it is trading at 1.89 but

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
greens12 Member Profile
 
Followed By 201
Posts 17,567
Boards Moderated 3
Alias Born 01/12/12
160x600 placeholder
Securities Registration Statement (s-1) "Edgar (US Regulatory)" - 10/17/2017 4:49:11 PM
Viking Therapeutics Announces Top-Line Results from Proof-of-Concept Study of VK0214 in In Vivo Model of X-Linked Adrenoleuko... "PR Newswire (US)" - 10/4/2017 7:05:00 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) "Edgar (US Regulatory)" - 9/29/2017 4:46:11 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 9/29/2017 7:06:35 AM
Viking Therapeutics Announces Purchase Agreements for up to $16.25 Million with Lincoln Park Capital "PR Newswire (US)" - 9/29/2017 7:05:00 AM
Viking Therapeutics to Host Key Opinion Leader Event to Discuss Musculoskeletal Therapeutics in Hip Fracture and Other Settin... "PR Newswire (US)" - 9/25/2017 7:30:00 AM
Viking Therapeutics Announces Results of Gene Expression Analysis from In Vivo Study of VK2809 in Non-Alcoholic Steatohepatit... "PR Newswire (US)" - 9/11/2017 7:05:00 AM
Viking Therapeutics Announces Presentation of Data from In Vivo Proof-of-Concept Study of VK2809 in Glycogen Storage Disease ... "PR Newswire (US)" - 9/7/2017 7:02:00 AM
Viking Therapeutics to Present at Rodman & Renshaw's 19th Annual Global Investment Conference "PR Newswire (US)" - 9/5/2017 7:30:00 AM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 8/9/2017 5:04:19 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 8/9/2017 4:17:47 PM
Viking Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update "PR Newswire (US)" - 8/9/2017 4:05:00 PM
Viking Therapeutics to Report Financial Results for Second Quarter 2017 After Market Close on August 9, 2017 "PR Newswire (US)" - 8/2/2017 7:30:00 AM
Viking Therapeutics Completes Enrollment in Phase 2 Study of VK5211 in Patients Recovering from Hip Fracture "PR Newswire (US)" - 7/12/2017 7:00:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 7/6/2017 8:11:19 AM
Viking Therapeutics Appoints Charles A. Rowland Jr. to Board of Directors "PR Newswire (US)" - 7/6/2017 8:00:00 AM
Confidential Treatment Order (ct Order) "Edgar (US Regulatory)" - 6/27/2017 4:31:03 PM
Small Company Offering and Sale of Securities Without Registration (d) "Edgar (US Regulatory)" - 6/22/2017 4:38:53 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 6/19/2017 4:33:42 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) "Edgar (US Regulatory)" - 6/15/2017 5:15:32 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 6/14/2017 10:02:28 AM
Viking Therapeutics Announces $4.3 Million Registered Direct Offering "PR Newswire (US)" - 6/14/2017 9:55:00 AM
Viking Therapeutics Announces Promising Top Line Results from In Vivo Study of VK2809 in Non-Alcoholic Steatohepatitis (NASH) "PR Newswire (US)" - 6/6/2017 7:14:00 AM
Viking Therapeutics to Present at Upcoming Investor Conferences "PR Newswire (US)" - 5/31/2017 7:30:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 5/24/2017 4:18:06 PM
greens12   Thursday, 10/05/17 02:30:16 PM
Re: zoomlik post# 731
Post # of 883 
Just because it is trading at 1.89 but worth 7.00 today does not mean that vk5211 fails.
The Delays in trials put a damper on things and Market Makers have suppressed it all summer. It's just now waking up..... when vk5211 news hits it could go to 7.00 fast.

VK 2809 Q1 data will take it 15.00 + JMHO


Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist